abstract |
Use of a compound of the formula (I) wherein R 1 is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR 7 R 8 , NR 6 COR 7 , NR 6 CO 2 R 9 and NR 6 SO 2 R 9 ; R 2 is selected from aryl attached via an unsaturated carbon; R 3 and R 4 are independently selected from H, alkyl, halogen, alkoxy, alkylthio, CN and NR 7 R 8 ; R 5 is selected from H, acyclic alkyl, COR 6 , CONR 7 R 8 , CONR 6 NR 7 R 8 , CO 2 R 9 and SO 2 R 9 ; R 6 , R 7 and R 8 are independently selected from H, alkyl and aryl or where R 7 and R 8 are in an NR 7 R 8 group R 7 and R 8 may be linked to form a hererocyclic group, or where R 6 , R 7 and R s are in a (CONR 6 NR 7 R s ) group, R 6 and R 7 may be linked to form a hererocyclic group; and R 9 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A 2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subect; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. |